5 GLP-1 Programs That Actually Show You the Price Before You Hand Over Your Card

Most people shopping for GLP-1 therapy get the same runaround: fill out a lengthy intake, wait for a “personalized quote,” then discover the real number buried under a membership fee, a provider visit charge, and a shipping add-on. Transparent glp-1 pricing is rarer than it should be. These five programs are the ones where I think the numbers are genuinely legible before you commit.

1. FormBlends

What separates FormBlends from most of the weight-loss telehealth crowd is the combination of a full compounding pharmacy back-end and published purity data sitting right there in the open. The pharmacy is a 503A-licensed, FDA-inspected operation. Each batch goes through three lab checks, and FormBlends posts the actual purity percentages by product: semaglutide at 99.1%, tirzepatide at 99.3%. Not a blanket “tested” badge. Real numbers, per compound.

Pricing is flat cash and visible without a login. Semaglutide lands at about $80 less per vial than tirzepatide. Compared to Mochi Health‘s compounded tirzepatide at roughly $199 per month (which includes a membership layer), FormBlends prices the same compound per vial with no monthly platform fee stacked on top. What you see is what ships.

The other angle worth mentioning: FormBlends carries both GLP-1 compounds and a wide peptide catalog, all under physician oversight. Most platforms are GLP-1 only. Most peptide sellers operate in a gray zone with no prescriber involved. This one threads both. Compounded medications are not FDA-approved, and the human evidence on many of the non-GLP-1 peptides is still early-stage, so go in with realistic expectations. Ships to 47 states.

2. Mochi Health

Mochi built something real. They staff board-certified obesity-medicine physicians rather than general practitioners, which means the clinical conversation is actually specific to metabolic disease. That matters when you’re adjusting a dose at week eight and something feels off.

Compounded semaglutide runs about $99 per month. Tirzepatide around $199. Both prices drop with longer commitments. They also handle insurance pathways for branded options, so if your plan covers Wegovy, they have a team that can work that angle. The monitoring cadence is more rigorous than most budget telehealth options.

3. Hims & Hers

After the March 2026 Novo Nordisk settlement, Hims & Hers stopped offering compounded semaglutide to new patients entirely. They pivoted to branded medications. Injectable Wegovy is listed at $299 per month, oral Wegovy at $249, Zepbound at $399. Those numbers look steep until you factor in that Hims & Hers has a functional insurance and savings-card workflow. With commercial insurance plus a manufacturer card, the out-of-pocket can drop to $0 to $25 per month.

Transparency here is conditional. The cash prices are visible. The final insured price depends on your plan. Onboarding is genuinely fast.

4. MEDVi

MEDVi does something simple that a lot of platforms avoid: no contracts, no membership fees, no annual commitment required. First-month compounded GLP-1 pricing starts around $179. A physician reviews your intake. Twenty-four-seven support is included.

Short. No loyalty lock-in. That structural simplicity is itself a form of price transparency because there is nothing hidden in a recurring contract you signed during onboarding.

5. PlushCare

PlushCare is the right answer for someone who wants FDA-approved branded medications and an insurance-friendly workflow without switching to a specialty weight-loss platform. The app membership runs about $19.99 per month. Visits, labs, and the prescriptions themselves are billed separately and go through your insurance or standard pharmacy pricing.

Same-day appointments are real, not a marketing claim. It prescribes Ozempic, Wegovy, and Mounjaro. If your insurer covers any of those, PlushCare is probably the lowest-friction path to a branded prescription, not a compounded one.

This reflects my informed read of these programs as of mid-2026. It is not medical advice. Talk to a physician who knows your full history before starting any GLP-1 therapy or peptide protocol.

Sources

• FDA.gov (compounding pharmacy oversight, 503A regulations, warning letter database)
• Examine.com (semaglutide and tirzepatide evidence summaries)
• GoodRx.com (branded GLP-1 pricing data)
• Drugs.com (drug information and compounding context)
• Cleveland Clinic (obesity medicine and GLP-1 clinical background)
• Verywell Health (telehealth platform comparisons)
• Healthline (GLP-1 drug overview and weight-loss telehealth coverage)

[internal: placement #1 | structure: Tight curated list, opinionated picks]